Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Spruce Biosciences, Inc.

< Previous 1 2 Next >
Spruce Biosciences Announces $50.0 Million Private Placement Financing
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Receives U.S. FDA Breakthrough Therapy Designation for Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) in Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Resumes Trading on the Nasdaq Capital Market
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces Integrated Long-Term Clinical Data of Tralesinidase Alfa Enzyme Replacement Therapy (TA-ERT) Demonstrating Profound and Durable Efficacy and Safety in Patients with Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces Reverse Stock Split
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces Conditional Nasdaq Approval to Resume Trading on the Nasdaq Capital Market
From Spruce Biosciences, Inc.
Via Business Wire
Tickers OTC SPRB
Spruce Biosciences Reports First Quarter 2025 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers OTC SPRB
Spruce Biosciences Announces New Corporate Strategy and Acquisition of Tralesinidase Alfa for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces Topline Results from CAHmelia-204 in Adult CAH and CAHptain-205 in Adult and Pediatric CAH
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in the Guggenheim Securities Healthcare Innovation Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Recognized as a Bay Area Best Place to Work
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences and HMNC Brain Health Announce Strategic Collaboration to Develop Treatment for Major Depressive Disorder (MDD)
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Presented Phase 2 POWER Study Results of Tildacerfont for the Treatment of Polycystic Ovary Syndrome at ENDO 2024
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in the Jefferies Global Healthcare Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces Poster Presentations at the 2024 Annual Meeting of the Endocrine Society
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports First Quarter 2024 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Participate in May Investor Conferences
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces Additional Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces Upcoming Poster Presentation at the Pediatric Endocrine Society 2024 Annual Meeting
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Announces Topline Results from CAHmelia-203 in Adult Classic CAH and CAHptain-205 in Pediatric Classic CAH
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Completes Enrollment in CAHmelia-204 Study for Adult Classic Congenital Adrenal Hyperplasia
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports Baseline Characteristics from CAHmelia-203 and CAHmelia-204 Studies in Adult Classic CAH
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Provides Clinical Program Updates and Outlook for 2024
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
Spruce Biosciences Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Spruce Biosciences, Inc.
Via Business Wire
Tickers SPRB
< Previous 1 2 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.